These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9690455)
1. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules. Liu J; Finke J; Krauss JC; Shu S; Plautz GE Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455 [TBL] [Abstract][Full Text] [Related]
2. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032 [TBL] [Abstract][Full Text] [Related]
3. CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn. Burgess KE; Yamamoto M; Prasad KV; Rudd CE Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9311-5. PubMed ID: 1384049 [TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor. Matsumura T; Krinock RA; Chang AE; Shu S Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926 [TBL] [Abstract][Full Text] [Related]
5. Characterization of p59fyn-mediated signal transduction on T cell activation. Fusaki N; Semba K; Katagiri T; Suzuki G; Matsuda S; Yamamoto T Int Immunol; 1994 Aug; 6(8):1245-55. PubMed ID: 7981151 [TBL] [Abstract][Full Text] [Related]
6. Age-related impairment of p56lck and ZAP-70 activities in human T lymphocytes activated through the TcR/CD3 complex. Fülöp T; Gagné D; Goulet AC; Desgeorges S; Lacombe G; Arcand M; Dupuis G Exp Gerontol; 1999 Apr; 34(2):197-216. PubMed ID: 10363787 [TBL] [Abstract][Full Text] [Related]
7. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. Yoshizawa H; Chang AE; Shu S J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710 [TBL] [Abstract][Full Text] [Related]
9. Contribution of p56lck to the upregulation of cytokine production and T cell proliferation by IL-2 in human CD3-stimulated T cell clones. Eljaafari A; Dorval I; Soula M; Quelvennec E; Pirenne H; Fagard R; Sterkers G Cell Immunol; 1995 Jan; 160(1):152-6. PubMed ID: 7842481 [TBL] [Abstract][Full Text] [Related]
10. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590 [TBL] [Abstract][Full Text] [Related]
11. Increase in the specific activity of p50csk in proliferating T cells correlates with decreased specific activity of p56lck and p59fyn and reduced phosphorylation of CD3 subunits. Orchansky PL; Ng DH; Johnson P; Teh HS Mol Immunol; 1996 Apr; 33(6):531-40. PubMed ID: 8700169 [TBL] [Abstract][Full Text] [Related]
12. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Inoue M; Plautz GE; Shu S Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987 [TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of protein tyrosine kinases p56lck and p59fyn, and altered tyrosine phosphorylation in murine AIDS. Trebak M; Lambert CA; Rahmouni S; Greimers R; Boniver J; Moutschen M Int Immunol; 1998 Oct; 10(10):1473-80. PubMed ID: 9796914 [TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507 [TBL] [Abstract][Full Text] [Related]
15. Interactions between the tyrosine kinases p56lck, p59fyn and p50csk in CD4 signaling in T cells. Baldari CT; Di Somma MM; Milia E; Bergman M; Telford JL Eur J Immunol; 1995 Apr; 25(4):919-25. PubMed ID: 7737294 [TBL] [Abstract][Full Text] [Related]
16. T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity. Levey DL; Srivastava PK J Exp Med; 1995 Oct; 182(4):1029-36. PubMed ID: 7561676 [TBL] [Abstract][Full Text] [Related]
17. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816 [TBL] [Abstract][Full Text] [Related]
18. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. Krauss JC; Strome SE; Chang AE; Shu S J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530 [TBL] [Abstract][Full Text] [Related]
20. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Raab M; Cai YC; Bunnell SC; Heyeck SD; Berg LJ; Rudd CE Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8891-5. PubMed ID: 7568038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]